John P. DeVincenzo, M.D.

Professor of Pediatrics, Division of Pediatric Infectious Diseases
Professor of Molecular Sciences, Microbiology, Immunology, and Biochemistry
Instructor, Biostatistics and Preventive Medicine
University of Tennessee Center for Health Sciences.
Clinical Director: Methodist/Le Bonheur Hospitals Molecular Diagnostics Laboratory
Clinical Director: Methodist/Le Bonheur Hospitals Clinical Virology Laboratory

MEMPHIS TN 381032893
Tel: (901) 287-6295

Narrative Biosketch

Dr DeVincenzo is a Professor of Pediatrics and Professor of Molecular Sciences, Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research has focused on understanding the pathogenesis of Respiratory Syncytial virus directly in children and using this understanding to develop therapeutic and prevention strategies against this virus.  He is the author of over 140 original published abstracts and papers on this subject.  Dr. DeVincenzo’s research initially focused on the immunogenetics of RSV disease and the interplay between viral dynamics and RSV disease severity in infants.  Subsequently, his research focus shifted to apply this knowledge of RSV dynamics to the development of novel therapeutics for RSV.  The development of RNA interference-based therapeutics for RSV has taken recent priority.  For his groundbreaking proof of concept work applying RNA interference concepts to develop human therapeutics, Dr. DeVincenzo’s study was listed as one of the most influential papers in medicine in 2010 (American Society for Microbiology).  Dr DeVincenzo received his undergraduate degree in biology from Stanford University, and then attended Vanderbilt Medical School where he became interested in pediatric infectious diseases and earned his MD degree.  His internship and residency were completed at U.C.L.A Center for Health Sciences where he had the honor to work with Dr. Jim Cherry.  After finishing his pediatrics training, Dr. DeVincenzo studied tropical medicine at Walter Reed and practiced general medicine in Central Africa before starting formal training in Pediatric Infectious Diseases at Boston Children’s Hospital and Harvard Medical School.  During this time he completed a research fellowship at the Dana Farber Cancer Institute working with his mentor, George Siber, in developing passive antibody approaches for RSV treatment and prevention.  Dr. DeVincenzo has conducted numerous clinical trials in children defining the role of prevention and therapeutic applications of monoclonal antibodies targeting RSV in infants and the immune suppressed.  He runs an active academic laboratory studying RSV and has received numerous honors for his research including honorary induction into Alpha Omega Alpha National Medical Honor Society (2009), the Healthcare Heroes Award for innovation (2008), and the best advance in Therapy and Prevention of a Microbial Disease (ICAAC 2007). Dr. DeVincenzo is currently also the medical director of the University affiliated Le Bonheur Children’s Hospital Virology Laboratory and the Methodist/Le Bonheur Molecular Diagnostics Laboratory. He is a practicing pediatric infectious disease specialist, lectures at the Medical School and is involved in award winning clinical teaching of medical students, residents, and fellows.


  1. Bagga, B, Woods, CW, Veldman, TH, Gilbert, A, Mann, A, Balaratnam, G, Lambkin-Williams, R, Oxford, JS, McClain, MT, Wilkinson, T, Nicholson, BP, Ginsburg, GS, Devincenzo, JP. Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther, 2013.
  2. Malboeuf, CM, Yang, X, Charlebois, P, Qu, J, Berlin, AM, Casali, M, Pesko, KN, Boutwell, CL, DeVincenzo, JP, Ebel, GD, Allen, TM, Zody, MC, Henn, MR, Levin, JZ. Complete viral RNA genome sequencing of ultra-low copy samples by sequence-independent amplification. Nucleic Acids Res, 41 (1), e13, 2013.
  3. Mundt, C, Sventitskiy, A, Cehelsky, JE, Patters, AB, Tservistas, M, Hahn, MC, Juhl, G, Devincenzo, JP. Assessing Modeled CO(2) Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants. ISRN Pediatr, 2012, 721295, 2012.
  4. DeVincenzo, JP. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir Ther, 17 (1 Pt B), 213-25, 2012.
  5. El Saleeby, CM, Bush, AJ, Harrison, LM, Aitken, JA, Devincenzo, JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis, 204 (7), 996-1002, 2011.
  6. El Saleeby, CM, Devincenzo, JP. Respiratory syncytial virus load and disease severity in the community. J Med Virol, 83 (5), 904-5, 2011.
  7. Zamora, MR, Budev, M, Rolfe, M, Gottlieb, J, Humar, A, Devincenzo, J, Vaishnaw, A, Cehelsky, J, Albert, G, Nochur, S, Gollob, JA, Glanville, AR. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med, 183 (4), 531-8, 2011.
  8. DeVincenzo, JP, Wilkinson, T, Vaishnaw, A, Cehelsky, J, Meyers, R, Nochur, S, Harrison, L, Meeking, P, Mann, A, Moane, E, Oxford, J, Pareek, R, Moore, R, Walsh, E, Studholme, R, Dorsett, P, Alvarez, R, Lambkin-Williams, R. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med, 182 (10), 1305-14, 2010.
  9. DeVincenzo, J, Lambkin-Williams, R, Wilkinson, T, Cehelsky, J, Nochur, S, Walsh, E, Meyers, R, Gollob, J, Vaishnaw, A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A, 107 (19), 8800-5, 2010.
  10. El Saleeby, CM, Li, R, Somes, GW, Dahmer, MK, Quasney, MW, DeVincenzo, JP. Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr, 156 (3), 409-14, 2010.
  11. Mishin, VP, Watanabe, M, Taylor, G, Devincenzo, J, Bose, M, Portner, A, Alymova, IV. N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site. J Virol, 84 (6), 3094-100, 2010.
  12. Carbonell-Estrany, X, Simões, EA, Dagan, R, Hall, CB, Harris, B, Hultquist, M, Connor, EM, Losonsky, GA, ,. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics, 125 (1), e35-51, 2010.
  13. DeVincenzo, JP. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. Early Hum Dev, 85 (10 Suppl), S31-5, 2009.
  14. Alvarez, R, Elbashir, S, Borland, T, Toudjarska, I, Hadwiger, P, John, M, Roehl, I, Morskaya, SS, Martinello, R, Kahn, J, Van Ranst, M, Tripp, RA, DeVincenzo, JP, Pandey, R, Maier, M, Nechev, L, Manoharan, M, Kotelianski, V, Meyers, R. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother, 53 (9), 3952-62, 2009.
  15. Lagos, R, DeVincenzo, JP, Muñoz, A, Hultquist, M, Suzich, J, Connor, EM, Losonsky, GA. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J, 28 (9), 835-7, 2009.
  16. Somers, CC, Ahmad, N, Mejias, A, Buckingham, SC, Carubelli, C, Katz, K, Leos, N, Gomez, AM, DeVincenzo, JP, Ramilo, O, Jafri, HS. Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial. Pediatr Allergy Immunol, 20 (5), 477-85, 2009.
  17. Miyairi, I, DeVincenzo, JP. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev, 21 (4), 686-703, 2008.
  18. DeVincenzo, JP, de Swart, RL, Osterhaus, AD. 2007 International Congress on Respiratory Viruses. Introduction. Pediatr Infect Dis J, 27 (10 Suppl), S53, 2008.
  19. DeVincenzo, JP. RNA interference strategies as therapy for respiratory viral infections. Pediatr Infect Dis J, 27 (10 Suppl), S118-22, 2008.
  20. DeVincenzo, J, Cehelsky, JE, Alvarez, R, Elbashir, S, Harborth, J, Toudjarska, I, Nechev, L, Murugaiah, V, Van Vliet, A, Vaishnaw, AK, Meyers, R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res, 77 (3), 225-31, 2008.
  21. El Saleeby, CM, Somes, GW, DeVincenzo, JP, Gaur, AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics, 121 (2), 235-43, 2008.
  22. DeVincenzo, J. Passive antibody prophylaxis for RSV. Pediatr Infect Dis J, 27 (1), 69-70, 2008.
  23. DeVincenzo, JP. A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: how real infants suffer. J Infect Dis, 195 (8), 1084-6, 2007.
  24. Miyairi, I, Causey, KT, DeVincenzo, JP, Buckingham, SC. Group B streptococcal ventriculitis: a report of three cases and literature review. Pediatr Neurol, 34 (5), 395-9, 2006.
  25. Avadhanula, V, Rodriguez, CA, Devincenzo, JP, Wang, Y, Webby, RJ, Ulett, GC, Adderson, EE. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol, 80 (4), 1629-36, 2006.
  26. DeVincenzo, JP. Factors predicting childhood respiratory syncytial virus severity: what they indicate about pathogenesis. Pediatr Infect Dis J, 24 (11 Suppl), S177-83, discussion S182, 2005.
  27. DeVincenzo, JP, El Saleeby, CM, Bush, AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis, 191 (11), 1861-8, 2005.
  28. Perkins, SM, Webb, DL, Torrance, SA, El Saleeby, C, Harrison, LM, Aitken, JA, Patel, A, DeVincenzo, JP. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol, 43 (5), 2356-62, 2005.
  29. Devincenzo, JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res, 56 (6), 914-7, 2004.
  30. DeVincenzo, JP, Hall, CB, Kimberlin, DW, Sánchez, PJ, Rodriguez, WJ, Jantausch, BA, Corey, L, Kahn, JS, Englund, JA, Suzich, JA, Palmer-Hill, FJ, Branco, L, Johnson, S, Patel, NK, Piazza, FM. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis, 190 (5), 975-8, 2004.
  31. El Saleeby, CM, Suzich, J, Conley, ME, DeVincenzo, JP. Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. Clin Infect Dis, 39 (2), e17-20, 2004.
  32. DeVincenzo, JP, Aitken, JB, Harrison, LG. Opportunities for early therapy of respiratory syncytial virus (RSV) infection: what happens before hospitalization. Antiviral Res, 62 (1), 47-51, 2004.
  33. DeVincenzo, JP, Aitken, J, Harrison, L. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J Pediatr, 143 (1), 123-6, 2003.
  34. Buckingham, SC, Jafri, HS, Bush, AJ, Carubelli, CM, Sheeran, P, Hardy, RD, Ottolini, MG, Ramilo, O, DeVincenzo, JP. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis, 185 (9), 1222-8, 2002.
  35. Buckingham, SC, Quasney, MW, Bush, AJ, DeVincenzo, JP. Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr Crit Care Med, 2 (4), 318-23, 2001.
  36. Luján-Zilbermann, J, Benaim, E, Tong, X, Srivastava, DK, Patrick, CC, DeVincenzo, JP. Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis, 33 (7), 962-8, 2001.
  37. Mitchell, LS, Taylor, B, Reimels, W, Barrett, FF, Devincenzo, JP. Adenovirus 7a: a community-acquired outbreak in a children's hospital. Pediatr Infect Dis J, 19 (10), 996-1000, 2000.
  38. DeVincenzo, JP. Therapy of respiratory syncytial virus infection. Pediatr Infect Dis J, 19 (8), 786-90; discussion 802-4, 811-3, 2000.
  39. Buckingham, SC, Bush, AJ, Devincenzo, JP. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J, 19 (2), 113-7, 2000.
  40. DeVincenzo, JP, Hirsch, RL, Fuentes, RJ, Top, FH. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant, 25 (2), 161-5, 2000.
  41. DeVincenzo, JP, Berning, SE, Peloquin, CA, Husson, RN. Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications. Ann Pharmacother, 33 (11), 1184-8, 1999.
  42. DeVincenzo, JP. Emerging and newly identified viral infections. Pediatr Ann, 25 (9), 511-7, 1996.
  43. DeVincenzo, JP, Burchet, SK. Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers. Pediatr Infect Dis J, 15 (5), 465-7, 1996.